Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis

NCT01591200 is registered in ClinicalTrials.gov with Stempeutics Research Pvt Ltd as lead sponsor.

NCT NCT01591200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01591200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis
Lead sponsor
Stempeutics Research Pvt Ltd
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
April 30, 2016
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alcoholic liver cirrhosis